Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

ClinicalTrials.gov ID: NCT00369434

Public ClinicalTrials.gov record NCT00369434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of DVS SR for Treatment of Vasomotor Symptoms Associated With Menopause

Study identification

NCT ID: NCT00369434
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Enrollment: 450 participants

Conditions and interventions

Conditions

Interventions

Desvenlafaxine succinate sustained-release (DVS SR) Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2006
Primary completion: Not listed
Completion: Jan 31, 2007
Last update posted: May 31, 2007

2006 – 2007

United States locations

U.S. sites: 34
U.S. states: 22
U.S. cities: 34

Facility	City	State	ZIP	Site status
Not listed	Montgomery	Alabama	36106	—
Not listed	Peoria	Arizona	85381	—
Not listed	Upland	California	91786	—
Not listed	Colorado Springs	Colorado	80910	—
Not listed	Brooksville	Florida	34613	—
Not listed	Inverness	Florida	34452	—
Not listed	Miami	Florida	33143	—
Not listed	New Port Richey	Florida	34652	—
Not listed	Ocala	Florida	34471	—
Not listed	St. Petersburg	Florida	33709	—
Not listed	Tampa	Florida	33606	—
Not listed	Decatur	Georgia	30033	—
Not listed	Savannah	Georgia	31406	—
Not listed	Boise	Idaho	83702	—
Not listed	Idaho Falls	Idaho	83404	—
Not listed	Overland Park	Kansas	66210	—
Not listed	Louisville	Kentucky	40291	—
Not listed	Portland	Maine	04102	—
Not listed	Rockville	Maryland	20852	—
Not listed	Billings	Montana	59102	—
Not listed	Las Vegas	Nevada	89146	—
Not listed	Albuquerque	New Mexico	87102	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Bismarck	North Dakota	58501	—
Not listed	Fargo	North Dakota	58104	—
Not listed	Cincinnati	Ohio	45267-0457	—
Not listed	Eugene	Oregon	97401	—
Not listed	Erie	Pennsylvania	16502	—
Not listed	Philadelphia	Pennsylvania	19114	—
Not listed	Wexford	Pennsylvania	15090	—
Not listed	Hilton Head Island	South Carolina	29926	—
Not listed	Midvale	Utah	84047	—
Not listed	Norfolk	Virginia	23507	—
Not listed	Richmond	Virginia	23294	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00369434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 31, 2007 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00369434 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →